Analysis of neurocognitive function and CNS endpoints in the PROTEA trial: darunavir/ritonavir with or without nucleoside analogues

Analysis of neurocognitive function and CNS endpoints in the PROTEA trial: darunavir/ritonavir with or without nucleoside analogues

Bibliographic Details
Main Authors:	Clarke, Amanda, Johanssen, Veronika, Gerstoft, Jan, Clotet, Bonaventura, Ripamonti, Diego, Murungi, Andrew, Bicer, Ceyhun, Blanca Hadacek, Maria, Moecklinghoff, Christiane
Format:	Online
Language:	English
Published:	International AIDS Society 2014
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4224914/

Similar Items

The PROTEA trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV-1 RNA below 50 copies/mL
by: Antinori, Andrea, et al.
Published: (2014)

No Difference in the Rate of Change in Telomere Length or Telomerase Activity in HIV-Infected Patients after Three Years of Darunavir/Ritonavir with and without Nucleoside Analogues in the MONET Trial
by: Solomon, Ajantha, et al.
Published: (2014)

Monotherapy with darunavir/ritonavir is effective and safe in clinical practice
by: Pasquau, Juan, et al.
Published: (2014)

Antiretroviral Simplification with Darunavir/Ritonavir Monotherapy in Routine Clinical Practice: Safety, Effectiveness, and Impact on Lipid Profile
by: Santos, José R., et al.
Published: (2012)

Knoxdaviesia proteae is not the only Knoxdaviesia-symbiont of Protea repens
by: Aylward, Janneke, et al.
Published: (2015)

Herb-drug interaction between Echinacea purpurea and darunavir/ritonavir in HIV-infected patients
by: Moltó, J, et al.
Published: (2010)

Effects of Tipranavir, Darunavir, and Ritonavir on Platelet Function, Coagulation, and Fibrinolysis in Healthy Volunteers
by: Kort, Jens J, et al.
Published: (2011)

Switching to dual therapy with darunavir/ritonavir and etravirine: a simplification strategy
by: Tyrer, M, et al.
Published: (2010)

The use of a darunavir/ritonavir once-daily regimen in two pregnant women
by: Lambert, JS, et al.
Published: (2010)

Physiologically Based Modelling of Darunavir/Ritonavir Pharmacokinetics During Pregnancy
by: Colbers, Angela, et al.
Published: (2015)

Analysis of major and minor IAS-USA PI mutations in the MONET trial of darunavir/ritonavir monotherapy versus DRV/r + 2NRTIs
by: Pulido, F, et al.
Published: (2010)

Metabolic: week 48 comparison of metabolic parameters and biomarkers in subjects receiving darunavir/ritonavir or atazanavir/ritonavir
by: Overton, T, et al.
Published: (2010)

Ritonavir-Boosted Darunavir Is Rarely Associated with Nephrolithiasis Compared with Ritonavir-Boosted Atazanavir in HIV-Infected Patients
by: Nishijima, Takeshi, et al.
Published: (2013)

Comparison of atazanavir/ritonavir and darunavir/ritonavir based antiretroviral therapy for antiretroviral naïve patients
by: Tony Antoniou, et al.
Published: (2017-04-01)

Once-daily dolutegravir is superior to once-daily darunavir/ritonavir in treatment-naïve HIV-1-positive individuals: 96 week results from FLAMINGO
by: Molina, Jean-Michel, et al.
Published: (2014)

Virological Efficacy in Cerebrospinal Fluid and Neurocognitive Status in Patients with Long-Term Monotherapy Based on Lopinavir/Ritonavir: An Exploratory Study
by: Santos, José R., et al.
Published: (2013)

Total and unbound darunavir pharmacokinetics in pregnant women infected with HIV-1: results of a study of darunavir/ritonavir 600/100 mg administered twice daily
by: Zorrilla, CD, et al.
Published: (2014)

Genome sequences of Knoxdaviesia capensis and K. proteae (Fungi: Ascomycota) from Protea trees in South Africa
by: Aylward, Janneke, et al.
Published: (2016)

The MONET trial: correlation between Hepatitis C coinfection and HIV RNA responses during darunavir/ritonavir monotherapy, for patients with HIV RNA <50 copies/mL at baseline
by: Arribas, Jose R, et al.
Published: (2010)

Cricket South Africa’s Protea Fire brand
by: Luisa, Mazinter, et al.
Published: (2017)

Changes in cerebral function parameters in HIV-1 infected subjects undergoing a treatment simplification to darunavir/ritonavir
by: Garvey, LJ, et al.
Published: (2010)

Health-related quality of life (HRQoL) assessment with once- and twice-daily darunavir/ritonavir (DRV/r) in the ODIN trial
by: Spinosa-Guzman, S, et al.
Published: (2010)

Population pharmacokinetic modelling of once-daily ritonavir-boosted darunavir in HIV-infected patients
by: Dickinson, L, et al.
Published: (2010)

Pharmacokinetic (PK) and pharmacodynamic analyses of once- and twice-daily darunavir/ritonavir (DRV/r) in the ODIN trial
by: Sekar, V, et al.
Published: (2010)

Improvements in Immune Function and Activation with 48-Week Darunavir/Ritonavir-Based Therapy: GRACE Substudy
by: Tsoukas, Christos, et al.
Published: (2013)

Cerebrospinal fluid viral breakthrough in two HIV-infected subjects on darunavir/ritonavir monotherapy
by: Gisslén, Magnus, et al.
Published: (2012)

Validation of Simultaneous Quantitative Method of HIV Protease Inhibitors Atazanavir, Darunavir and Ritonavir in Human Plasma by UPLC-MS/MS
by: Mishra, Tulsidas, et al.
Published: (2014)

Efficacy of Once Daily Darunavir/Ritonavir in PI-Naïve, NNRTI-Experienced Patients in the ODIN Trial
by: Geretti, Anna Maria, et al.
Published: (2015)

Once-daily maraviroc versus tenofovir/emtricitabine each combined with darunavir/ritonavir for initial HIV-1 treatment
by: Stellbrink, Hans-Jürgen, et al.
Published: (2016)

Differential Effects of Viremia and Microbial Translocation on Immune Activation in HIV-Infected Patients Throughout Ritonavir-Boosted Darunavir Monotherapy
by: BenMarzouk-Hidalgo, Omar J., et al.
Published: (2015)

Simulation of the impact of rifampicin on darunavir/ritonavir PK and dose adjustment strategies in HIV-infected patients: a population PK approach
by: Dickinson, Laura, et al.
Published: (2014)

Efficacy of a dual therapy based on darunavir/ritonavir and etravirine in ART-experienced patients
by: Ignacio Bernardino, Jose, et al.
Published: (2014)

Lamivudine plus darunavir boosted with ritonavir as simplification dual regimen in HIV-infected patients
by: Luis Casado, Jose, et al.
Published: (2014)

Effectiveness and durability of darunavir/ritonavir (DRV/r) in DRV/r-experienced HIV-1-infected patients in routine clinical practice
by: Antinori, Andrea, et al.
Published: (2014)

Resistance mutations in protease gene at baseline are not related to virological failure in patients treated with darunavir/ritonavir monotherapy
by: Gutierrez-Liarte, Angela, et al.
Published: (2014)

Safety and therapeutic efficacy of the switch to maraviroc+darunavir/ritonavir in HIV/HCV coinfected patients: initial results from GUSTA study
by: Gagliardini, Roberta, et al.
Published: (2014)

Effect of Monotherapy with Darunavir/Ritonavir on Viral Load in Seminal Fluid, and Quality Parameters of Semen in HIV-1-Positive Patients
by: Lopez-Ruz, Miguel A., et al.
Published: (2016)

Developmental Plasticity in Protea as an Evolutionary Response to Environmental Clines in the Cape Floristic Region
by: Carlson, Jane E., et al.
Published: (2012)

Guiding the Seafarers: The South African Hydrographic Office and the Contribution of the Three Proteas
by: Thean Potgieter
Published: (2013-02-01)

Antifungal Streptomyces spp. Associated with the Infructescences of Protea spp. in South Africa
by: Human, Zander R., et al.
Published: (2016)